Dr. Garassino on Subgroup Analyses of the VISION Trial in METex14-Altered NSCLC

Video

Marina Garassino, MD, discusses the results of subgroup analyses of the phase 2 VISION trial in MET exon 14 skipping mutation–positive non-small cell lung cancer.

Marina Garassino, MD, professor of Medicine, Hematology and Oncology, The University of Chicago Department of Medicine, discusses the results of subgroup analyses of the phase 2 VISION trial (NCT02864992) in MET exon 14 (METex14) skipping mutation–positive non-small cell lung cancer (NSCLC).

The VISION trial evaluated the efficacy of tepotinib (Tepmetko) in patients with advanced or metastatic METex14-altered NSCLC. The results of a subgroup analysis of the study, which were presented during the 2021 ESMO Congress, demonstrated that patients older than the age of 75 years derived a robust response with durable clinical activity with tepotinib, Garassino says. This activity was similar to that observed in younger patients, Garassino adds.

 Overall, the objective response rate was 52.2% in patients under the age of 75 years and 44.9% in patients at least 75 years old, Garassino says. Moreover, the confidence intervals overlapped, indicating tepotinib is an effective treatment option for elderly patients with METex14-altered NSCLC, Garassino concludes.

Related Videos
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD
Kari Wisinski, MD, Endowed Professor of Hematology and Oncology, chief, Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health; associate director, Clinical Research, co-lead, Breast Cancer Disease Oriented Team, UW Carbone Cancer Center
Susan C. Modesitt, MD, FACOG, FACS, professor, Department of Gynecology and Obstetrics, director, Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine
Nikhil A. Gopal, MD